|
| 38010394 | Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. | Cancer Chemother Pharmacol | 2024 |
| 38010394 | Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. | Cancer Chemother Pharmacol | 2024 |
| 36302173 | Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. | Clin Cancer Res | 2023 |
| 36302173 | Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. | Clin Cancer Res | 2023 |
| 37672694 | Atezolizumab for Advanced Alveolar Soft Part Sarcoma. | N Engl J Med | 2023 |
| 37637936 | Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. | Cancer Res Commun | 2023 |
| 37550087 | Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource. | Mol Cancer Ther | 2023 |
| 36960342 | Data augmentation and multimodal learning for predicting drug response in patient-derived xenografts from gene expressions and histology images. | Front Med (Lausanne) | 2023 |
| 37330147 | Exogenous DNA enhances DUOX2 expression and function in human pancreatic cancer cells by activating the cGAS-STING signaling pathway. | Free Radic Biol Med | 2023 |
| 37267580 | The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. | J Clin Oncol | 2023 |
| 36813886 | Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal E<sub>max</sub> regressions. | Cancer Chemother Pharmacol | 2023 |
| 37322121 | The NCI-MATCH trial: lessons for precision oncology. | Nat Med | 2023 |
| 36870109 | Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo. | Redox Biol | 2023 |
| 37045940 | DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. | Sci Rep | 2023 |
| 36662819 | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). | Clin Cancer Res | 2023 |
| 37531248 | The New NCI Precision Medicine Trials. | Clin Cancer Res | 2023 |
| 36525371 | Expanding access to early phase trials: the CATCH-UP.2020 experience. | JNCI Cancer Spectr | 2023 |
| 37550087 | Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource. | Mol Cancer Ther | 2023 |
| 37672694 | Atezolizumab for Advanced Alveolar Soft Part Sarcoma. | N Engl J Med | 2023 |
| 37637936 | Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. | Cancer Res Commun | 2023 |
| 37531248 | The New NCI Precision Medicine Trials. | Clin Cancer Res | 2023 |
| 37322121 | The NCI-MATCH trial: lessons for precision oncology. | Nat Med | 2023 |
| 37045940 | DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. | Sci Rep | 2023 |
| 37267580 | The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. | J Clin Oncol | 2023 |
| 37330147 | Exogenous DNA enhances DUOX2 expression and function in human pancreatic cancer cells by activating the cGAS-STING signaling pathway. | Free Radic Biol Med | 2023 |
| 36960342 | Data augmentation and multimodal learning for predicting drug response in patient-derived xenografts from gene expressions and histology images. | Front Med (Lausanne) | 2023 |
| 36813886 | Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal E<sub>max</sub> regressions. | Cancer Chemother Pharmacol | 2023 |
| 36870109 | Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo. | Redox Biol | 2023 |
| 36662819 | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). | Clin Cancer Res | 2023 |
| 36525371 | Expanding access to early phase trials: the CATCH-UP.2020 experience. | JNCI Cancer Spectr | 2023 |
| 34716194 | Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. | Clin Cancer Res | 2022 |
| 35964611 | Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. | Lancet | 2022 |
| 35876604 | Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs. | Mol Cancer Ther | 2022 |
| 35689374 | Bilateral Pulmonary Embolism Masked by New-Onset Atrial Fibrillation with Rapid Ventricular Rate: The Role of Mechanical Thrombectomy. | Am J Case Rep | 2022 |
| 35803440 | The beginning of GPX2 and 30 years later. | Free Radic Biol Med | 2022 |
| 36068285 | Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors. | NPJ Precis Oncol | 2022 |
| 35982453 | 3'-[<sup>18</sup>F]fluoro-3'-deoxythymidine ([<sup>18</sup>F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor. | J Transl Med | 2022 |
| 35472132 | ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies. | Cancer Res | 2022 |
| 34524425 | A cross-study analysis of drug response prediction in cancer cell lines. | Brief Bioinform | 2022 |
| 35333495 | Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute-Designated Cancer Centers. | Cancer J | 2022 |
| 35237050 | PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. | Onco Targets Ther | 2022 |
| 34450618 | TPWshiny: an interactive R/Shiny app to explore cell line transcriptional responses to anti-cancer drugs. | Bioinformatics | 2022 |
| 34716194 | Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. | Clin Cancer Res | 2022 |
| 34996889 | Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. | Nat Commun | 2022 |
| 35263120 | Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. | J Clin Oncol | 2022 |
| 35803440 | The beginning of GPX2 and 30 years later. | Free Radic Biol Med | 2022 |
| 35472132 | ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies. | Cancer Res | 2022 |
| 35689374 | Bilateral Pulmonary Embolism Masked by New-Onset Atrial Fibrillation with Rapid Ventricular Rate: The Role of Mechanical Thrombectomy. | Am J Case Rep | 2022 |
| 36068285 | Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors. | NPJ Precis Oncol | 2022 |
| 35964611 | Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. | Lancet | 2022 |